Cargando…

Development of Respimat(®) Soft Mist™ Inhaler and its clinical utility in respiratory disorders

The Respimat(®) Soft Mist™ Inhaler (SMI) (Boehringer Ingelheim International GmbH, Ingelheim, Germany) was developed in response to the need for a pocket-sized device that can generate a single-breath, inhalable aerosol from a drug solution using a patient-independent, reproducible, and environmenta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalby, Richard N, Eicher, Joachim, Zierenberg, Bernd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417885/ https://www.ncbi.nlm.nih.gov/pubmed/22915941 http://dx.doi.org/10.2147/MDER.S7409

Ejemplares similares

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

Reduced Environmental Impact of the Reusable Respimat(®) Soft Mist™ Inhaler Compared with Pressurised Metered-Dose Inhalers
por: Hänsel, Michaela, et al.
Publicado: (2019)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

Long-term safety of tiotropium delivered by Respimat(®) SoftMist™ Inhaler: patient selection and special considerations
por: Tan, Ching Kuo, et al.
Publicado: (2016)

Higher lung deposition with Respimat(®) Soft Mist(™) Inhaler than HFA-MDI in COPD patients with poor technique
por: Brand, Peter, et al.
Publicado: (2008)

A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old
por: Kamin, Wolfgang, et al.
Publicado: (2015)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Patient perceptions of the re-usable Respimat(®) Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
por: Dreher, Michael, et al.
Publicado: (2021)

Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
por: Dhand, Rajiv, et al.
Publicado: (2019)

Pharmacokinetics and tolerability (Study 1) with particular reference to ocular safety (Study 2) of tiotropium Respimat(®) Soft Mist(™) Inhaler: findings from two dose-ranging studies in healthy men
por: Feifel, Ulrich, et al.
Publicado: (2008)

Reducing carbon footprint by switching to reusable soft-mist inhalers
por: Janson, Christer, et al.
Publicado: (2023)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

Inhaler usability of a pressurized metered dose inhaler and a soft mist inhaler in patients with COPD: A simulated-use study
por: Ding, Bo, et al.
Publicado: (2018)

Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices
por: Hira, Daiki, et al.
Publicado: (2018)

Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered‐Dose Inhaler
por: MacGregor, TR, et al.
Publicado: (2016)

Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis
por: Navaie, Maryam, et al.
Publicado: (2020)

Technical Evaluation of Soft Mist Inhaler Use in Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study
por: Zhang, Wei, et al.
Publicado: (2020)

Pharmacokinetic Study of Epinephrine Hydrofluoroalkane (Primatene MIST) Metered-Dose Inhaler
por: Kerwin, Edward M., et al.
Publicado: (2020)

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT(®) Re-usable Inhaler
por: Ortsäter, Gustaf, et al.
Publicado: (2019)

Clinical effectiveness of the Respimat(®) inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
por: Ram, Felix SF, et al.
Publicado: (2011)

Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study
por: Dal Negro, Roberto W., et al.
Publicado: (2017)

In Vitro Determination of Respimat(®) Dose Delivery in Children: An Evaluation Based on Inhalation Flow Profiles and Mouth–Throat Models
por: Bickmann, Deborah, et al.
Publicado: (2016)

Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat
por: Davis, Kimberly H., et al.
Publicado: (2017)

Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
por: Erelel, Mustafa, et al.
Publicado: (2021)

Night of the Mist
por: Colwell, Catherine
Publicado: (1960)

TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow
por: Mahler, Donald A, et al.
Publicado: (2021)

Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
por: Singer, David, et al.
Publicado: (2020)

Assessment of Patient Experiences with Respimat(®) in Everyday Clinical Practice
por: Taube, Christian, et al.
Publicado: (2020)

Wing Patterns in the Mist
por: Martin, Arnaud, et al.
Publicado: (2010)

The CERN version of MIST
por: McCarroll, S J
Publicado: (1963)

The Cholera Mist Again
Publicado: (1866)

Dust, Mist and Clouds
Publicado: (1883)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies
por: Ichinose, Masakazu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c95r9gc7ci9b1m7nhij629t5ju